Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

Summary

The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.

Eligibility

Inclusion Criteria:

* Signed informed consent
* Patient with histologically proven TNBC
* Indication for neo-adjuvant chemo-immunotherapy treatment
* Age between 18 and 75
* Affiliated or beneficiary of a social protection scheme

Exclusion Criteria:

* Pregnant or breast-feeding women
* Contraindication to immunotherapy
* Inflammatory breast cancer (T4d)
* Metastatic patients
* Allergies to iodine or gadolinium
* Patient with an augmentation prosthesis (for angiography/mammography)
* Claustrophobic patients
* Renal contraindication to contrast products according to SFR-CIRTACI
* Ferromagnetic material
* Uncontrolled diabetes (blood glucose \>10 mmol/L)
* Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).
* Patient under guardianship, curatorship or safeguard of justice

Conditions3

Browse More Trials